UK Approves Icotrokinra for Psoriasis After 4 Trials Involving 2,500 People
Key Facts
The UK Medicines and Healthcare products Regulatory Agency approved icotrokinra hydrochloride, known as Icotyde, on October 23, 2026, to treat moderate-to-severe plaque psoriasis. The decision allows use of the treatment in adults and adolescents who meet the age and weight criteria and are candidates for systemic therapy. The agency said its decision was based on data from four Phase 3 clinical trials involving 2,500 people. Among the participants were 72 adolescents aged 12 to under 18 who weighed at least 40 kg. The approval adds an oral option for this patient group in the UK, according to the agency's statement.
The approval defines the eligible group as adults and adolescents aged 12 and older who weigh at least 40 kg and are candidates for systemic therapy. Approved use is therefore tied to age and weight criteria and the need for this type of treatment; the decision does not cover everyone with plaque psoriasis regardless of their condition. The four trials showed the drug was effective at Week 16 compared with placebo among the groups included in the studies. This timing provides a defined framework for assessing the results on which the agency relied. The approval statement did not specify the numerical difference in efficacy between the drug and placebo.
The evidence base comprises four Phase 3 trials, the stage whose results the agency cited in support of the approval. The total number of participants was 2,500, including 72 adolescents aged 12 to under 18 who weighed at least 40 kg. Including these adolescents matches the age and weight criteria in the approved scope of use. At Week 16, the four studies showed icotrokinra was effective compared with placebo among the participating groups. This result links the size of the trial base to the population covered by the decision, although the agency's statement did not provide detailed response-rate figures.
Icotrokinra is taken as a 200 mg tablet once daily, according to the agency. The drug works by selectively binding to and blocking the interleukin-23 receptor. This mechanism describes a specific pathway through which the treatment works, while the dosage specifies its daily regimen. The tablet form is among the options available to eligible patients who need systemic therapy. The approval statement did not include sales estimates or a commercial launch date, and it provided no details on the expected financial impact for Johnson & Johnson.
The agency said safety monitoring will remain part of the drug's use and that icotrokinra's safety will continue to be closely monitored. It urged patients and healthcare professionals to report suspected side effects through the Yellow Card scheme. It also said product information and patient leaflets would be published on the agency's product website within 7 days of approval. That deadline is the next step specified in its statement following the decision on October 23. Safety monitoring and side-effect reporting will continue as the treatment is used.